|
Main | | | | | | | | | |
| Name | Founded | HQ | Round | Size | Investors | Date | Notes | Valuation |
| Altos | | | Series A | 3000 | ARCH, Bezos | | | |
| ElevateBio | | | Series D | 401 | Matrix, Softbank, Surveyor, Redmile, Novo Nordisk, Fidelity, EcoR1, Samsara | 5/24/2023 | | |
| Insitro | 2018 | South San Francisco, CA | Series C | 400 | | | | |
| Tessera Therapeutics | 2018 | | Series C | 300 | Softbank | | | 1700 |
| ArsenalBio | | | Series B | 221 | Softbank | 4/19/2022 | | |
| XtalPi | | | | | | | | |
| Biosplice Therapeutics | | | | | | | | |
| Abogen Biosciences | 2019 | | | | | | Chinese RNA | |
| Mojave Pharma | | | | | | | | |
| Laronde | | | | | | | | |
| Kallyope | | | | | | | | |
| Kriya Therapeutics | | | | | | | | |
| Genor Biopharma | | | | | | | | |
| Metis Pharmaceuticals | 2020 | | Series B | 150m | | 4/6/2022 | Chinese | |
| Generate Biomedicines | | | | | | | | |
| RayzeBio | 2018 | | Series D | 160m | Sofinnova, Viking, Wellington | 9/13/2022 | Radiopharma | |
| RayzeBio | 2018 | | Series C | 108m | Venrock | 6/15/2021 | | |
| RayzeBio | 2018 | | Series B | 105m | Venrock | 12/8/2020 | | |
| RayzeBio | 2018 | | Series A | 45m | venBio, Versant | 10/14/2020 | | |
| Insilico Medicine | | | | | | | | |
| Odyssey Therapeutics | | | | | | | | |
| Maze Therapeutics | | | | | | | | |
| TauRx Pharmaceuticals | | | | | | | | |
| Vividion Therapeutics | | | | | | | | |
| Tizona Therapeutics | | | | | | | | |
| Charm Therapeutics | 2021 | | | 20m | | 4/14/2023 | | |
| Pathos | 2020 | | | 20m | | 3/2/2023 | | |
| Aqemia | | | | | | | | |
| Mindrank | 12/23/2020 | | | 19m | | 12/15/2021 | | |
| Ventus Therapeutics | | | | | | | | |
| Alto Neuroscience | | | | | | | | |
| Affinivax | | | | | | | | |
| Pionyr Immunotherapeutics | | | | | | | | |
| Areteia Therapeutics | | | | | | | | |
| Grey Wolf Therapeutics | | | | | | | | |
| Elicio Therapeutics | | | | | | | | |
| Amolyt Pharma | | | | | | | | |
| Ribon Therapeutics | | | | | | | | |
| Atomwise | | | | | | | | |
| Nimbus | | | | | | | | |
| Acelyrin | | | | | | | | |
| Eikon Therapeutics | | | Series B | 500 | | | | |
| Akamis Bio | | | | | | | | |
| Structure Therapeutics | | | | | | | | |
| Treeline Biosciences | | | | | | | | |
| Tmunity Therapeutics | | | | | | | | |
| Scribe Therapeutics | | | | | | | | |
| Orna Therapeutics | | | | | | | | |
| Remix Therapeutics | | | | | | | | |
| Arch Oncology | | | | | | | | |
| A2 Biotherapeutics | | | | | | | | |
| Gilgamesh Pharmaceuticals | | | | | | | | |
| Capsida | | | | | | | | |
| Carisma Therapeutics | | | | | | | | |
| Forge Biologics | | | | | | | | |
| LatchBio | | | | | | | | |
| Pathalys Pharma | | | | | | | | |
| Kernel | | | | | | | | |
| Cardurion | | | | | | | | |
| Dyno Therapeutics | | | | | | | | |
| BigHat Biosciences | | | Series B | 75m | | | | |
| Genesis Biomedicines | | | Series A | 52m | | | | |
| Shape Therapeutics | | | | | | | | |
| Alloy Therapeutics | | | | | | | | |
| Goldfinch Biopharma | | | | | | | | |
| Evozyne | | | | | | | | |
| ReCode Therapeutics | | | | | | | | |
| Exarta | | | | | | | | |
| Affilogic | | | | | | | | |
| Faeth Therapeutics | | | | | | | | |
| Manifold Bio | 2019 | Boston, MA | | | | | | |
| Avista Therapeutics | | | | | | | | |
| InnoRNA | | | | | | | | |
| Empirico | | | | | | | | |
| 1859, Inc. | 2019 | San Diego, CA | Series A | 40m | Northpond Ventures, OMX Ventures | 2/7/2022 | | |
| SyntheticGestalt | | | Series A | 11m | | | | |
| Neomorph | | | | | | | | |
| Moonlake Immunotherapeutics | | | | | | | IL-17 A/F mab | |
| Meissa Vaccines | | | | | | | | |
| Wren Therapeutics | 2019? | | Series A | 18m GBP | | 1/1/2019 | Alzheimer's amyloid aggregation inhibitor | |
| Aria Pharmaceuticals | | | | | | | | |
| FogPharma | | | Series C | 107m | | | Beta-Catenin | |
| Cellarity | | | Series C | 121m | | | | |
| Abyssinia Biologics | | | | | | | | |
| Intima Bioscience | | | | | | | | |
| Noema Pharma | | | | | | | | |
| Microgen | | | | | | | Microgen.ru | |
| Metagenomi | | | | | | | | |
| Intarcia | | | | | | | | |
| HotSpot Therapeutics | | | | | | | ABBV deal | |
| Anima Biotech | | | | | | | ABBV deal | |
| Camp4 Therapeutics | 2018 | Cambridge, MA | Series A-1 | 30m | | 5/31/2018 | | |
| Camp4 Therapeutics | 2018 | Cambridge, MA | Series A-2 | 45m | | | | |
| Camp4 Therapeutics | 2018 | Cambridge, MA | Series B | 100m | | | | |
| Antiverse | | | | | | | GPCR antibodies | |
| Ensoma | | | Series B | 85m | | | | |
| Ensoma | | | Series A | 70m | Catalio, Solasta, QIA, 5AM, Cormorant | | | |
| SetPoint Medical | | | Series C | 42m | | | | |
| SetPoint Medical | | | Series D | 30m | | | | |
| PharmCADD | | | Series B | 16m | | | | |
| Athos Therapeutics | | | Series A | 15m | | | | |
| Vevo Therapeutics | | | Seed | 12m | | | | |
| Verseon | | | | | | | | |
| Nutcracker Therapeutics | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| Quris | | | Seed | 9m | Softbank | 12/20/2022 | Software | |